key: cord-1043631-3td5faf4
authors: Walker, Alexander P; Fan, Haitian; Keown, Jeremy R; Grimes, Jonathan M; Fodor, Ervin
title: Identification of guanylyltransferase activity in the SARS-CoV-2 RNA polymerase
date: 2021-03-18
journal: bioRxiv
DOI: 10.1101/2021.03.17.435913
sha: b32e43a9a432e2370625ea29db7a12a7625dc412
doc_id: 1043631
cord_uid: 3td5faf4

SARS-CoV-2 is a positive-sense RNA virus that is responsible for the ongoing Coronavirus Disease 2019 (COVID-19) pandemic, which continues to cause significant morbidity, mortality and economic strain. SARS-CoV-2 can cause severe respiratory disease and death in humans, highlighting the need for effective antiviral therapies. The RNA synthesis machinery of SARS-CoV-2 is an ideal drug target and consists of non-structural protein 12 (nsp12), which is directly responsible for RNA synthesis, and numerous co-factors that are involved in RNA proofreading and 5’ capping of viral mRNAs. The formation of the 5’ cap-1 structure is known to require a guanylyltransferase (GTase) as well as 5’ triphosphatase and methyltransferase activities. However, the mechanism of SARS-CoV-2 mRNA capping remains poorly understood. Here we show that the SARS-CoV-2 RNA polymerase nsp12 functions as a GTase. We characterise this GTase activity and find that the nsp12 NiRAN (nidovirus RdRP-associated nucleotidyltransferase) domain is responsible for carrying out the addition of a GTP nucleotide to the 5’ end of viral RNA via a 5’ to 5’ triphosphate linkage. We also show that remdesivir triphosphate, the active form of the antiviral drug remdesivir, inhibits the SARS-CoV-2 GTase reaction as efficiently as RNA polymerase activity. These data improve understanding of coronavirus mRNA cap synthesis and highlight a new target for novel or repurposed antiviral drugs against SARS-CoV-2. Importance SARS-CoV-2 is a respiratory RNA virus responsible for the Coronavirus Disease 2019 (COVID-19) pandemic. Coronaviruses encode an RNA polymerase which, in combination with other viral proteins, is responsible for synthesising capped viral mRNA. mRNA cap synthesis requires a guanylyltransferase enzyme; here we show that the SARS-CoV-2 guanylyltransferase is located in the viral RNA polymerase, and we identify the protein domain responsible for guanylyltransferase activity. Furthermore we demonstrate that remdesivir triphosphate, the active metabolite of remdesivir, inhibits both the guanylyltransferase and RNA polymerase functions of the SARS-CoV-2 RNA polymerase. These findings improve understanding of the coronavirus mRNA cap synthesis mechanism, in addition to highlighting a new target for the development of therapeutics to treat SARS-CoV-2 infection.

and 5' capping of viral mRNAs. The formation of the 5' cap-1 structure is known to require a 23 guanylyltransferase (GTase) as well as 5' triphosphatase and methyltransferase activities. 24 However, the mechanism of SARS-CoV-2 mRNA capping remains poorly understood. Here we 25 show that the SARS-CoV-2 RNA polymerase nsp12 functions as a GTase. We characterise this 26 GTase activity and find that the nsp12 NiRAN (nidovirus RdRP-associated 27 nucleotidyltransferase) domain is responsible for carrying out the addition of a GTP nucleotide 28 to the 5' end of viral RNA via a 5' to 5' triphosphate linkage. We also show that remdesivir 29 triphosphate, the active form of the antiviral drug remdesivir, inhibits the SARS-CoV-2 GTase 30 reaction as efficiently as RNA polymerase activity. These data improve understanding of 31 coronavirus mRNA cap synthesis and highlight a new target for novel or repurposed antiviral 32 drugs against SARS-CoV-2. 33 Importance 34 SARS-CoV-2 is a respiratory RNA virus responsible for the Coronavirus Disease 2019 (COVID-19) 35 pandemic. Coronaviruses encode an RNA polymerase which, in combination with other viral 36 3 proteins, is responsible for synthesising capped viral mRNA. mRNA cap synthesis requires a 37 guanylyltransferase enzyme; here we show that the SARS-CoV-2 guanylyltransferase is located 38 in the viral RNA polymerase, and we identify the protein domain responsible for 39 guanylyltransferase activity. Furthermore we demonstrate that remdesivir triphosphate, the 40 active metabolite of remdesivir, inhibits both the guanylyltransferase and RNA polymerase 41 functions of the SARS-CoV-2 RNA polymerase. These findings improve understanding of the Specifically, nsp13, nsp14, and nsp16 are involved in m 7 G cap synthesis as a 5' triphosphatase, 68 N7-methyltransferase, and 2'-O-methyltransferase, respectively(9-12). m 7 G cap synthesis 69 pathways also require a guanylyltransferase (GTase) enzyme, which was recently reported to 70 reside in nsp12, the RNA-dependent RNA polymerase (RdRP) component of the RTC(13). 71 Like the RNA polymerases of other nidoviruses, SARS-CoV-2 nsp12 includes a 250-amino acid 72 nidovirus RdRP-associated nucleotidyltransferase (NiRAN) domain at the N-terminus(14, 15). As 73 the name suggests, the NiRAN domain is implicated in covalently binding to GTP and UTP 74 nucleotides, and this domain is thought to be involved in the GTase activity of nsp12(13, 14). In 75 order to function as a processive RNA polymerase nsp12 must form a complex with nsp7 and 76 nsp8(16). Structures of the nsp7/8/12 RNA polymerase complex from SARS-CoV-2 have been 77 solved by cryo-EM, and these show that nsp12 is the core of the complex while nsp8 forms an 

SARS-CoV-2 RNA polymerase purification and RNA synthesis activity 93 In order to gain insight into the function of the SARS-CoV-2 RNA polymerase we first aimed to 94 establish an in vitro RNA synthesis activity assay, measuring extension of a 20 nucleotide (nt) 95 primer (LS2) along a 40nt RNA template (LS1) (Fig. 1A) (16). We individually expressed wild type 96 nsp7, nsp8 and nsp12 from SARS-CoV-2, and mixed the purified proteins to reconstitute the 97 nsp7/8/12 RNA polymerase complex (Fig. 1B, C) . In addition, we expressed and purified 98 D760A/D761A mutant nsp12, in which two aspartic acid residues coordinating magnesium in 99 6 the RdRP active site had been substituted for alanine (Fig. 1B) . In the presence of RNA template 100 and rNTPs, the wild type nsp7/8/12 complex was able to extend the LS2 primer along the LS1 101 template in a time-dependent manner to produce a 40nt major product (Fig. 1D) . In contrast, a 102 complex of nsp7/8/12 with D760A/D761A nsp12 was unable to extend the LS2 primer. Nsp13 is thought to function directly upstream of the GTase in the m 7 G capping pathway by 113 acting as a 5' triphosphatase ( Fig. 2A )(9). Therefore, we used purified nsp13 to generate a 114 diphosphorylated 20nt model RNA substrate for the GTase reaction, after first confirming the in 115 vitro 5' triphosphatase activity of nsp13 on a γ-32 P-ATP substrate (Fig. 2B, C) . We incubated the 116 diphosphorylated 20nt RNA with nsp7, nsp8, nsp12 and α-32 P-GTP, then separated the reaction 117 products by denaturing PAGE (Fig. 2D ). In reactions which included nsp12 we observed a 118 radiolabelled product running slightly slower than the 20nt marker, which was dependent on 119 the presence of diphosphorylated RNA. Since the equine arteritis virus (EAV) RNA polymerase 120 7 can nucleotidylate using either GTP or UTP, we also incubated nsp12 and the diphosphorylated 121 RNA substrate with α-32 P-UTP ( Fig. 2E ) (14) . In this case we did not observe any radiolabelled 122 product, suggesting that the reaction is nucleotide-specific. 123 To confirm that nsp12 performs a GTase reaction we compared its activity to that of vaccinia 124 capping enzyme, a known GTase(26). When we incubated vaccinia capping enzyme with the 125 diphosphorylated RNA and α-32 P-GTP it produced a radiolabelled product with the same 126 mobility as the product made by nsp12 (Fig. 2F ). To further confirm that this was the capped 127 RNA product of a GTase reaction, we performed enzymatic digestions of the substrate and 128 product RNAs. First, we treated the substrate RNA with alkaline phosphatase (AP) or RNA 5' 129 pyrophosphohydrolase (RppH) to produce dephosphorylated and monophosphorylated RNAs 130 respectively, then performed the GTase reaction (Fig. 2G ). Vaccinia capping enzyme and nsp12 131 both displayed substantially reduced activity in the presence of dephosphorylated or 132 monophosphorylated RNAs, indicating that a diphosphorylated RNA substrate is required. 133 Second, after running the GTase reaction we treated the reaction products with AP or RppH 134 (Fig. 2H) . The radiolabelled products made by vaccinia capping enzyme and nsp12 were not 135 sensitive to dephosphorylation with AP, but were sensitive to RppH. This enzymatic profile is 136 characteristic of a GTase product; the cap-like structure in the product RNA protects 5' 137 phosphates from AP, however, RppH can degrade the product RNA by cleaving internally in the 138 5' triphosphate(27). Collectively, these data show that SARS-CoV-2 nsp12 has GTase activity in 139 vitro, which is consistent with other recent data(13). The nsp12 NiRAN domain is responsible for guanylyltransferase activity 142 Next, we investigated which domain in nsp12 is responsible for performing the GTase reaction. 143 The EAV RNA polymerase becomes nucleotidylated in the NiRAN domain, so we hypothesised 144 that the equivalent domain in SARS-CoV-2, consisting of nsp12 amino acid residues 1-250, could 145 be important for GTase activity as suggested previously (Fig. 3A)(13, 14) . We therefore made 146 alanine substitutions at amino acid residues R116, D126 and D218, which are located in the 147 NiRAN domain nucleotide binding pocket and have previously been identified as important for 148 EAV RNA polymerase nucleotidylation activity as well as SARS-CoV growth (Fig. 3B , C)(14). 149 We performed GTase reactions using the mutant nsp12 proteins, and found that all NiRAN 150 domain mutations significantly reduced GTase activity (Fig. 3D) . The D218A mutation was the 151 most inhibitory, reducing GTase activity to approximately 10% of wild type nsp12. This result is 152 consistent with a cryo-EM structure which shows that D218 coordinates a magnesium ion in the 153 NiRAN domain, and therefore has a key role in nucleotide binding (Fig. 3B)(18) . Interestingly, 154 the D760A/D761A RdRP active site mutation also reduced GTase activity to approximately 40% 155 of wild type nsp12. In contrast to their inhibitory effects on GTase activity, none of the NiRAN 156 domain mutations significantly disrupted nsp12 RNA polymerase activity in the presence of 157 nsp7 and nsp8 (Fig. 3E) . Together, these data demonstrate that the NiRAN domain is important 158 for GTase activity. 159 We then investigated whether the NiRAN domain alone is capable of performing the GTase 160 reaction. We expressed and purified the SARS-CoV-2 NiRAN domain alone, and performed 161 GTase reactions using either full-length nsp12 or the isolated NiRAN domain (Fig. 4A, B) . The (Fig. 4C) . Furthermore, the radiolabelled product made by the NiRAN domain 169 reaction was sensitive to degradation by RppH but not AP (Fig. 4D) . These results are similar to 170 those obtained using full-length nsp12 and vaccinia capping enzyme, confirming that the NiRAN 171 domain alone is capable of performing the GTase reaction. Remdesivir triphosphate inhibits guanylyltransferase activity 174 Our data show that SARS-CoV-2 nsp12 has GTase activity, a function which requires nucleotide 175 binding and therefore could be inhibited by nucleotide analogue drugs. One such nucleotide 176 analogue is remdesivir triphosphate, active metabolite of the drug remdesivir which potently 177 inhibits SARS-CoV-2 growth (Fig. 5A)(23) . 178 We first tested the inhibitory effect of remdesivir triphosphate on RNA polymerase activity 179 using the nsp7/8/12 complex, where the drug inhibited activity with an IC 50 of 1.42mM, which 180 is in agreement with previous reports that remdesivir triphosphate is an RNA polymerase 181 inhibitor in vitro (Fig. 5B, E)(19, 28) . Next, we titrated remdesivir triphosphate into nsp12 GTase 182 reactions, where the drug also inhibited product accumulation with an IC 50 of 0.43mM (Fig. 5C,   183 10 E). To confirm that remdesivir triphosphate inhibits the GTase reaction by binding directly to 184 the NiRAN domain, we then titrated the drug into reactions performed using the isolated 185 NiRAN domain (Fig. 5D, E) . Under these conditions the drug also inhibited product 186 accumulation, with a much lower IC 50 of 4.06µM. Together, these data demonstrate that 187 remdesivir triphosphate inhibits the GTase function of SARS-CoV-2 nsp12 in addition to RNA 188 polymerase activity in vitro. is not recognised as non-self (35) . 213 We find that the nsp12 NiRAN domain is capable of performing the GTase reaction alone, 214 indicating this domain contains the GTase active site (Fig. 4B) . However, the isolated NiRAN remdesivir in vivo could be explained by a dual mechanism of action. We find that remdesivir 242 triphosphate inhibits nsp12 GTase activity with a slightly lower IC 50 than RNA polymerase 243 activity in vitro, and it is unclear which of these inhibitory activities is most important for 244 reducing viral growth (Fig. 5E) . We also find that the drug inhibits the NiRAN domain GTase 245 reaction with a much lower IC 50 , which could be due to mechanistic differences in the GTase 246 reaction compared to full-length nsp12, or because remdesivir triphosphate binding to the 247 nsp12 RdRP domain reduces efficacy. The SARS-CoV-2 nsp12 NiRAN domain is an attractive 248 13 target for future antiviral drugs as it could be targeted by nucleotide analogues, and in silico 249 studies propose that certain kinase inhibitors may be able to bind to the NiRAN domain(41). 250 The GTase activity assay we have established here could function as a useful tool to assess the 251 potency of these compounds. 252 In summary, we have identified that the SARS-CoV-2 RNA polymerase is a GTase enzyme, which 253 provides a complete enzymatic model for coronavirus m 7 G cap synthesis and is consistent with 254 a recent independent study(13). We additionally show that the NiRAN domain is responsible for 255 GTase activity, which presents a new target for novel or repurposed antiviral drugs against 256 SARS-CoV-2. the presence of 5mM MgCl 2 for 5 mins at 30°C, followed by heat inactivation of nsp13 at 70°C 298 for 5 mins. The resulting diphosphorylated RNA stock was used for all GTase reactions. To test 299 nsp13 activity, 4.75µM ATP mixed with 0.25µM γ-32 P-ATP was used as a substrate. As a positive 300 control, 0.5U/µl FastAP Thermosensitive Alkaline Phosphatase (Thermo) was incubated with 301 4.75µM ATP and 0.25µM γ-32 P-ATP for 1 hour at 37°C. Reactions were stopped by addition of 302 80% formamide and 10mM EDTA, followed by heating to 95°C for 3 mins. Reaction products 303 were resolved by 20% denaturing PAGE with 7M urea, and visualised by phosphorimaging on a 304 Fuji FLA-5000 scanner. Data were analysed using ImageJ and Prism 9 (GraphPad).

Guanylyltransferase in vitro activity assays 307 Complexes of nsp7, nsp8 and nsp12 were formed as described above, and nsp12 was used for 308 GTase reactions unless indicated otherwise. Where indicated, 5µM diphosphorylated 20mer 309 16 RNA substrate (see above) was pre-treated with 0.3U/µl FastAP Thermosensitive Alkaline 310 Phosphatase (Thermo) at 37°C for 1 hour. Alternatively, 5µM diphosphorylated 20mer RNA 311 substrate was pre-treated with 0.5U/µl RNA 5' Pyrophosphohydrolase (NEB) in 1x NEBuffer 2 312 (NEB) at 37°C for 1 hour. Enzymes were heat inactivated at 75°C for 5 mins before the resulting 313 RNA substrates were used in GTase reactions. 314 To run the GTase reaction, 500nM protein was incubated with 1µM diphosphorylated or 315 phosphatase-treated 20mer RNA, 0.05µM α-32 P-UTP or α-32 P-GTP, 5mM MgCl 2 , 10mM KCl, 1U 316 RNasin (Promega) and 1mM DTT at 30°C for 240 mins unless stated otherwise. GTase reactions 317 involving vaccinia capping enzyme were run for 60 mins under the same conditions, using 318 0.01U/µl vaccinia capping enzyme (NEB) instead of SARS-CoV-2 protein. 319 Where indicated, completed GTase reactions were treated with 0.3U/µl FastAP 320 Thermosensitive Alkaline Phosphatase (Thermo) at 37°C for 1 hour. Alternatively, the reactions 321 were treated with 0.5U/µl RNA 5' Pyrophosphohydrolase (NEB) in 1x NEBuffer 2 (NEB) at 37°C 322 for 1 hour. All reactions were stopped by addition of 80% formamide and 10mM EDTA, 323 followed by heating to 95°C for 3 mins. Reaction products were resolved by 20% denaturing 324 PAGE with 7M urea, and visualised by phosphorimaging on a Fuji FLA-5000 or Typhoon FLA-325 9500 scanner. Data were analysed using ImageJ and Prism 9 (GraphPad). input from all authors. 336 We have no conflicts of interest to declare. 337 338

The species Severe acute respiratory syndrome-related 342 coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

Genome Composition and Divergence of 345 the Novel Coronavirus (2019-nCoV) Originating in China

Nidovirales: Evolving the largest 347 RNA virus genome

The Nonstructural Proteins Directing Coronavirus

RNA Synthesis and Processing

Coronavirus biology and 352 replication: implications for SARS-CoV-2

Coronaviruses use discontinuous extension for synthesis of 354 subgenome-length negative strands

The coding capacity of SARS-CoV-2

The Architecture of SARS-CoV

Enzymatic Activities Associated with Severe Acute Respiratory Syndrome Coronavirus 363

Functional screen reveals 365 SARS coronavirus nonstructural protein nsp14 as a novel cap N7 methyltransferase

Unique and conserved features of genome and

proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage

Coronavirus Nonstructural Protein 16 Is a Cap-0 Binding Enzyme 373

Possessing (Nucleoside-2′O)-Methyltransferase Activity

SARS-CoV-2 Replication and Transcription Complex Reveals an Intermediate State in Cap 377 Synthesis

Discovery of an essential nucleotidylating activity 381 associated with a newly delineated conserved domain in the RNA polymerase-containing 382 protein of all nidoviruses

Structure of the RNA-dependent RNA 386 polymerase from COVID-19 virus

One severe acute respiratory syndrome coronavirus 389 protein complex integrates processive RNA polymerase and exonuclease activities

Structure of 392 replicating SARS-CoV-2 polymerase

Structural basis for 395 helicase-polymerase coupling in the SARS-CoV-2 replication-transcription complex

Structural basis for inhibition of the RNA-dependent RNA polymerase from

CoV-2 by remdesivir

Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase

Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-408 2 lethal mutagenesis

Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase, a Key Drug Target 411 for COVID-19

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus 414 (2019-nCoV) in vitro

Remdesivir in 419 adults with severe COVID-19: a randomised, double-blind, placebo-controlled, 420 multicentre trial

Conventional and unconventional 422 mechanisms for capping viral mRNA

Catalytic activity of vaccinia mRNA capping enzyme subunits 424 coexpressed in Escherichia coli

The bacterial enzyme RppH triggers messenger 426 RNA degradation by 5′ pyrophosphate removal

Mechanism of SARS-CoV-2 polymerase stalling by 429 remdesivir

The SARS-coronavirus nsp7+nsp8 431 complex is a unique multimeric RNA polymerase capable of both de novo initiation and 432 primer extension

Biochemical characterization of a recombinant 434 SARS coronavirus nsp12 RNA-dependent RNA polymerase capable of copying viral RNA 435 templates

A second, non-canonical RNA-dependent RNA 438 polymerase in SARS coronavirus

Structural 440 basis and functional analysis of the SARS coronavirus nsp14-nsp10 complex

Crystal structure and 444 functional analysis of the SARS-coronavirus RNA cap 2′-o-methyltransferase nsp10/nsp16 445 complex

Biochemical and structural insights into the mechanisms of sars 448 coronavirus RNA ribose 2′-O-methylation by nsp16/nsp10 protein complex

Discriminating self from non-self in nucleic acid sensing

Structural insights into RNA polymerases of 453 negative-sense RNA viruses

RNA synthesis and capping by nonsegmented negative strand 455 RNA viral polymerases: Lessons from a prototypic virus

Discovery of an RNA virus 3′→5′ exoribonuclease that is critically involved in 458 coronavirus RNA synthesis

High Fidelity of Murine Hepatitis 460

Virus Replication Is Decreased in nsp14 Exoribonuclease Mutants

Unconventional Mechanism of mRNA Capping by the RNA-463

Dependent RNA Polymerase of Vesicular Stomatitis Virus

In silico 465 characterization of the NiRAN domain of RNA-dependent RNA polymerase provides 466 insights into a potential therapeutic target against SARS-CoV2

MultiBac: Expanding the research 469 toolbox for multiprotein complexes

Isolation and 471 characterization of the positive-sense replicative intermediate of a negative-strand RNA 472 virus

 328 We thank Yuliana Yosaatmadja and Opher Gileadi for providing purified SARS-CoV-2 nsp13. 329